Alzheimer - International Biopharmaceutical Industry

news

Biogen CEO to step down as company pulls back from Alzheimer’s drug

Biogen is searching for a new CEO along with additional ways to cut costs after another quarter of paltry sales for its closely watched Alzheimer’s disease drug. Onc...

9 May 2022 news Alzheimer | Biogen

Continue Reading →

news

Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan

Biogen’s drug for Alzheimer’s disease, once considered a blockbuster-in-waiting, has run into so many obstacles since gaining approval last June that the company is n...

9 May 2022 news Aduhelm | Alzheimer

Continue Reading →

news

Biogen pulls European application for Aduhelm in another setback for the Alzheimer’s drug

Dive Brief: Biogen has withdrawn a request to start selling its Alzheimer's disease drug in Europe, marking the latest setback in the company's efforts to ramp up ...

25 April 2022 news Aduhelm | Alzheimer

Continue Reading →

news

Medicare finalizes policy limiting coverage of Biogen Alzheimer’s drug

Medicare will not pay for Biogen's new Alzheimer's medicine unless prospective patients are enrolled in a clinical trial, the U.S. government said Thursday in a decis...

11 April 2022 news Alzheimer | Biogen

Continue Reading →

news

FDA panel to review once-rejected Acadia drug for psychosis

Dive Brief: After receiving a rejection last year, Acadia said Wednesday that the Food and Drug Administration agreed to review its resubmitted application to expa...

14 March 2022 news Acadia | Alzheimer

Continue Reading →

news

Biogen, struggling to sell Alzheimer’s drug, begins layoffs to save money

Biogen has begun to lay off employees as part of a previously disclosed effort to lower annual expenses by half a billion dollars. The move comes as the Cambridge, Ma...

4 March 2022 news Alzheimer | Biogen

Continue Reading →

news

Roche, nearing major trial readouts, starts new Alzheimer’s drug study

Dive Brief: Roche is expanding clinical testing of its experimental Alzheimer's disease drug gantenerumab, announcing Thursday the start of a late-stage trial in p...

4 March 2022 news Aduhelm | Alzheimer

Continue Reading →

news

Al Sandrock, former top Biogen scientist, to join drug discovery startup’s board

Dive Brief: Al Sandrock, a former top Biogen executive who led development of the company's Alzheimer's drug Aduhelm, is joining the board of directors at Verge Ge...

10 February 2022 news Al Sandrock | Alzheimer

Continue Reading →

news

Biogen’s Alzheimer’s drug sales remain slow as company warns of further cost cuts

Biogen recorded $1 million in revenue from its new treatment for Alzheimer's disease in the last quarter of 2021, offering the latest evidence that the drug, which ca...

6 February 2022 news Alzheimer | Biogen

Continue Reading →

news

Lilly slows FDA submission of Alzheimer’s drug after Medicare decision

Dive Brief: Eli Lilly is pushing back the timing for when it expects to finish submitting an application for U.S. approval of its experimental drug for Alzheimer's...

6 February 2022 news Alzheimer | Drug

Continue Reading →